111
Participants
Start Date
June 27, 2023
Primary Completion Date
September 30, 2025
Study Completion Date
March 31, 2026
Durvalumab
Participants will receive 1500 mg at Day 1 and later receive as monotherapy starting at Week 4 for every 4 weeks through IV infusion
Tremelimumab
Participants will receive single dose of 300 mg through IV infusion at Day 1
Research Site, Barcelona
Research Site, Turin
Research Site, Marseille
Research Site, Seongnam-si
Research Site, Gyeonggi-do
Research Site, Córdoba
Research Site, Rozzano
Research Site, Milan
Research Site, Lübeck
Research Site, Madrid
Research Site, Madrid
Research Site, Pamplona
Research Site, Rennes
Research Site, Padua
Research Site, Detroit
Research Site, Cologne
Research Site, Pisa
Research Site, Frankfurt
Research Site, Shreveport
Research Site, Napoli
Research Site, La Jolla
Research Site, Clichy
Research Site, Bobigny
Research Site, Créteil
Research Site, Hanoi
Research Site, Singapore
Research Site, Singapore
Research Site, Singapore
Research Site, Berlin
Research Site, Hong Kong
Research Site, Shatin
Research Site, Kanazawa
Research Site, Kashiwa
Research Site, Matsuyama
Research Site, Musashino-shi
Research Site, Osakasayama-shi
Research Site, Yokohama
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Lead Sponsor
AstraZeneca
INDUSTRY